🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2025-522027-95-00
Authorised Phase III

Fluorescence Intraoperative Surgical Margin Analysis in Head and Neck Cancer: Clinical Validation

2025-522027-95-00 · tracked via the Priya Life Science EU tracker
Sponsor
Universitair Medisch Centrum Groningen
Sponsor type
Hospital/Clinic/Other health care facility
Therapeutic area
Neoplasms
Decision date
19/01/2026
Enrollment target
120
Sites
Netherlands

Condition studied

oral squamous cell carcinoma

Investigational medicinal product(s)

CETUXIMAB

Eligibility

Age group
65+ years, 18-64 years
Sex
Female, Male

Primary endpoint

Compare surgical outcome in terms of margin status between the intervention cohort and the standard of care cohort

Endpoint detail

Determining diagnostic parameters (including predictive values, sensitivity, specificity, type I & II errors) of fluorescence imaging for identifying inadequate tumor margins., Implementation of an intraoperative feedback workflow between the pathology department and surgery team on the margin assessment by FI., Retrospective comparison between standard fluorescence imaging devices and a novel technique using dual aperture fluorescence imaging as an exploratory objective.

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-522027-95-00 on CTIS ↗ ← All trials in the EU